Build · Insilico Medicine
QPCTL immuno-oncology program: candidate nomination in 9 months, co-developed with Fosun
Insilico Medicine is an AI-native biotech running its own generative-chemistry drug-discovery platform (Pharma.AI), and licensing it through partnerships with major pharma companies.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Source
Published by Insilico Medicine on its own site — read the original case study on insilico.com ↗
More like this
Related use cases
- 01Rentosertib (ISM001-055), a TNIK inhibitor for idiopathic pulmonary fibrosis: first drug with both an AI-discovered target and AI-designed molecule to reach Phase II; preclinical candidate nomination in 18 months (vs. ~4.5-year industry average) after synthesizing only 78 molecules; Phase IIa showed dose-dependent lung-function improvement
- 02DDR1 kinase inhibitor: proof-of-concept identifying potent inhibitors in 21 days using generative chemistry (Chemistry42
- 03~$1.2B collaboration referenced as a partnership milestone
- 04$80M upfront licensing deal for ISM3091
- 05Partnership potentially worth >$500M
- 06Partnership worth >$100M